Malondialdehyde in benign prostate hypertrophy: a useful marker?
| Autor: | Sebastiano Gangemi, Giuseppe Di Pasquale, Antonio Tomaino, Giuseppe Fraccica, Rosaria Alba Merendino, Francesco Salvo, Paola Lucia Minciullo, Antonella Saija |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2003 |
| Předmět: |
Male
medicine.medical_specialty Prostate-specific antigen Immunology Prostatic Hyperplasia Urology medicine.disease_cause urologic and male genital diseases Benign tumor Muscle hypertrophy chemistry.chemical_compound Internal medicine Malondialdehyde medicine lcsh:Pathology Humans skin and connective tissue diseases Aged business.industry urogenital system Cancer Cell Biology Middle Aged Prostate-Specific Antigen medicine.disease Uremia Oxidative Stress Endocrinology chemistry Biomarker (medicine) Benign prostate hypertrophy business Biomarkers Oxidative stress Research Article lcsh:RB1-214 |
| Zdroj: | Mediators of Inflammation, Vol 12, Iss 2, Pp 127-128 (2003) Mediators of Inflammation |
| ISSN: | 0962-9351 |
| DOI: | 10.1080/0962935031000097745 |
| Popis: | Benign prostate hypertrophy (BPH) is the most common benign tumor in men due to obstruction of the urethra and, finally, uremia. Malondialdehyde (MDA) is a product derived from peroxidation of polyunsaturated fatty acids and related esters. Evaluation of MDA in serum represents a non-invasive biomarker of oxidative stress. Prostate-specific antigen (PSA) is a sensitive marker for prostatic hypertrophy and cancer. We analyzed MDA serum levels to evaluate the oxidative stress in BPH. To this end, 22 BPH patients and 22 healthy donors were enrolled. Data show an increase of MDA level in BPH patients and a positive correlation between PSA and MDA levels. In conclusion, we describe a previously unknown relationship between PSA and MDA as an index of inflammation and oxidative stress in BPH. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|